Posted by Michael Wonder on 02 Mar 2024
Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran
1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study.
Now the manufacturer cites the same study in its dossier on patisiran sodium, but interprets it completely differently.
